Last reviewed · How we verify
pegylated IFNa2b
At a glance
| Generic name | pegylated IFNa2b |
|---|---|
| Also known as | PEG-Intron, PEG, 12 kDalton pegylated interferon alpha 2b |
| Sponsor | Biolex Therapeutics, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pegylated IFNa2b CI brief — competitive landscape report
- pegylated IFNa2b updates RSS · CI watch RSS
- Biolex Therapeutics, Inc. portfolio CI